Sustained small interfering RNA delivery by mesoporous silicon particles

Cancer Research

Volumn 70, Issue 9, 2010, Pages 3687-3696

  Tanaka, Takemi ^a,e   Mangala, Lingegowda S ^b   Vivas Mejia, Pablo E ^g   Nieves Alicea, René ^a   Mann, Aman P ^a   Mora, Edna ^b,f,g   Han, Hee Dong ^b   Shahzad, Mian M K ^b,d   Liu, Xuewu ^a,e   Bhavane, Rohan ^a   Gu, Jianhua ^a   Fakhoury, Jean R ^a,e   Chiappini, Ciro ^e   Lu, Chunhua ^b   Matsuo, Koji ^b   Godin, Biana ^a   Stone, Rebecca L ^b   Nick, Alpa M ^b   Lopez Berestein, Gabriel ^b   Sood, Anil K ^b   Ferrari, Mauro ^a,b,c,e   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Rice University   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f Department of Surgery ^*  (Puerto Rico)

^g UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIOLEOYL PHOSPHATIDYLCHOLINE; EPHRIN A2; NANOPARTICLE; ONCOPROTEIN; PHOSPHATIDYLCHOLINE; SILICON; SMALL INTERFERING RNA; STAGE 1 MICROPARTICLE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BIOCOMPATIBILITY; BIODEGRADATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; POROSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; GENE THERAPY; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; PHOSPHATIDYLCHOLINES; RECEPTOR, EPHA2; RNA, SMALL INTERFERING; SILICON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951699994     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3931     Document Type: Article

References (49)

1. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-719 (Pubitemid 44764213)
2. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86. (Pubitemid 46770900)
3. Heidel JD, Yu Z, Liu JY, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A 2007;104:5715-5721 (Pubitemid 47175600)
4. Desai AA, Schilsky RL, Young A, et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 2005;16:958-965 (Pubitemid 40903923)
5. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008;105:11915-11920
6. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-1007
7. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-114
8. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007;8:173-184
9. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659-668
10. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008;3:703-717
11. Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci 2008;97:237-250
12. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-372
13. Landen CN, Jr., Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-6918
14. Lara PN, Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728-1733
15. Tasciotti E, Liu XW, Bhavane R, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 2008;3:151-157 (Pubitemid 351355132)
16. Halder J, Kamat AA, Landen CN, Jr., et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-4924 (Pubitemid 44338579)
17. Thaker PH, Yazici S, Nilsson MB, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005;11:4923-4933 (Pubitemid 41557213)
18. Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006;27:5307-5314 (Pubitemid 44080296)
19. Decuzzi P, Lee S, Decuzzi M, Ferrari M. Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng 2004;32:793-802.
20. Stein E, Lane AA, Cerretti DP, et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Gene Dev 1998;12:667-678 (Pubitemid 28134299)
21. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007;109:332-340 (Pubitemid 46106248)
22. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-462 (Pubitemid 41724921)
23. Robbins MA, Rossi JJ. Sensing the danger in RNA. Nat Med 2005;11:250-251
24. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15:3770-3780
25. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-6052 (Pubitemid 32039378)
26. Cheng N, Brantley DM, Liu H, et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002;1:2-11. (Pubitemid 36330206)
27. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145-5150 (Pubitemid 39099789)
28. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-2306
29. Kinch MS, Moore MB, Harpole DH, Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613-618
30. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494-501.
31. Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006;107:2330-2338 (Pubitemid 43345552)
32. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001;3:527-530 (Pubitemid 32422092)
33. Miao H, Li DQ, Mukherjee A, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009;16:9-20.
34. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000;19:5614-5619
35. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009;101:1193-1205
36. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002;20:1006-1010
37. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149.
38. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11:50-55 (Pubitemid 40215837)
39. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995;92:3318-3322
40. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycolliposomes upon repeated injection. J Pharmacol Exp Ther 2001;298:607-612 (Pubitemid 32673411)
41. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 2008;60:1266-1277
42. Foraker AB, Walczak RJ, Cohen MH, Boiarski TA, Grove CF, Swaan PW. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res 2003;20:110-116
43. Delouise LA, Miller BL. Enzyme immobilization in porous silicon: quantitative analysis of the kinetic parameters for glutathione-S-transferases. Anal Chem 2005;77:1950-1956
44. Prestidge CA, Barnes TJ, Lau CH, Barnett C, Loni A, Canham L. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug deliv 2007;4:101-110 (Pubitemid 46389909)
45. Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009;8:331-336
46. Zhang K, Loong SL, Connor S, et al. Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice. Clin Cancer Res 2005;11:7532-7537 (Pubitemid 41507715)
47. Cubillos-Ruiz JR, Engle X, Scarlett UK, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009;119:2231-2244
48. Canham LT. Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater 1995;7:1033-1037
49. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: Does geometry really matter? Pharm Res 2009;26:235-243